Table 2 Base case cost-effectiveness results
|  | Cost | Incremental Cost | QALY | Incremental QALY | ICER (incremental) | ICER vs. standard care | p (C/E) @ 20 k | p (C/E) @ 20 k vs. standard care |
|---|---|---|---|---|---|---|---|---|
Base case: Full associative effect of AKI mitigation on a) the risk of CKD within the first year, b) half the associative effect on the need for ICU, c) half the associative effect on hospital/ICU LOS, and d) no associative effect on 90-day mortality. | ||||||||
Standard care (Scr) | £22,978 | – | 6.07277 | – | – | – | 64.5% | – |
Test 1 (NephroCheck) | £23,016 | £38 | 6.07313 | 0.00036 | £105,965 | £105,965 | 29.7% | 32.0% |
Test 3 (NGAL urine - BioPorto) | £23,049 | Dominated | 6.07290 | Dominated | Dominated | £539,041 | 5.3% | 11.0% |
Test 2 (NGAL plasma - BioPorto) | £23,064 | Dominated | 6.07290 | Dominated | Dominated | £633,846 | 0.3% | 7.3% |
Test 4 (NGAL urine - ARCHITECT) | £23,065 | Dominated | 6.07289 | Dominated | Dominated | £725,061 | 0.0% | 6.3% |